Vertex Pharma (NASDAQ:VRTX) reported Q1 EPS of $3.52, $0.04 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.1 billion versus the consensus estimate...
Investing.com - Vertex (NASDAQ:VRTX) reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that topped expectations. Vertex announced earnings...
By Geoffrey Smith Investing.com -- U.S. markets are waking up with a post-Fed hangover, but solid earnings from various sectors of the economy after hours on Wednesday are set to...
Every legendary investor worth their salt has some sort of phrase to describe what investors should be doing right this very minute.“Be fearful when others are greedy, be...
Q1 wasn’t a good period for the equity market overall, and the small-cap stocks. We could call Q1 a strange period as well. The small-cap Russell 2000 Index dropped more than...
Biotechnology is one of the most volatile sectors in the market, which is why it’s been so interesting to see certain stocks in that area showing lots of relative strength...
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. It offers medicines for people with serious diseases with a focus on specialty markets. The Company's four medicines are being used to treat most of the people with CF in North America, Europe and Australia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Neutral | Neutral | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Sell | Strong Buy | Neutral | Strong Buy |
| Summary | Strong Sell | Neutral | Buy | Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 102.63 | 103.09 | 99.52 | +0.16 | +0.16% | 26.49M | NASDAQ | |||
| 90.82 | 91.15 | 89.32 | -1.17 | -1.27% | 5.76M | NYSE | |||
| 112.61 | 113.36 | 111.86 | -3.29 | -2.83% | 1.12M | NYSE | |||
| 62.04 | 62.61 | 59.01 | +5.85 | +10.41% | 7.57M | NYSE | |||
| 37.05 | 37.60 | 36.96 | -0.59 | -1.57% | 2.58M | NYSE | |||
| 168.98 | 173.85 | 168.58 | -5.48 | -3.14% | 913.37K | NASDAQ | |||
| 95.52 | 96.07 | 95.12 | +0.02 | +0.02% | 151.48K | NYSE | |||
| 10.79 | 10.99 | 10.45 | -0.30 | -2.71% | 2.10M | NASDAQ | |||
| 245.96 | 248.78 | 245.30 | -3.01 | -1.21% | 357.78K | NYSE | |||
| 12.55 | 12.67 | 12.53 | -0.040 | -0.32% | 38.16K | NYSE | |||
| 24.08 | 24.15 | 24.04 | -0.41 | -1.67% | 3.28K | OTC Markets | |||
| 1.165 | 1.185 | 1.14 | -0.0250 | -2.10% | 1.35M | NYSE | |||
| 7.96 | 8.24 | 7.91 | -0.33 | -3.98% | 1.05M | NYSE | |||
| 85.08 | 86.51 | 84.96 | -2.02 | -2.32% | 230.87K | NASDAQ | |||
| 1.63 | 1.76 | 1.58 | +0.180 | +12.41% | 9.85M | NASDAQ |